Periostin as a predictor of severe exacerbations in asthma

Not Applicable

Completed

• Conditions: Asthma; Respiratory - Asthma

• Registration Number: ACTRN12615000503527
• Lead Sponsor: Medical Research Institute of New Zealand

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-05-20
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 230

Inclusion Criteria

Participants from:
-New Zealand Respiratory Health Survey (NZRHS) (ACTR number 12610000666022) phase two and
-Longitudinal study of serum periostin levels in asthma (PER02)(ACTR number 12614000235606)
Able to perform written informed consent

Exclusion Criteria

-Known pregnancy
-Surgery within last 3 months, determined at investigator discretion (this includes all major surgery requiring general anaesthetic, dental extractions and root canal procedures. This does not include minor procedures including, but not limited to, mole or wart removal, dental fillings etc)
-Bone fracture within last 3 months
-Active (current, or within the 3 weeks prior to the visit) upper or lower respiratory tract infection
-Any other safety concern at the investigator's discretion

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The association between serum periostin and severe asthma exacerbations in adult asthmatics. The details of asthma exacerbations will be collected from participants directly via the Asthma Exacerbation Questionnaire, as well as consulting their General Practitioner (GP) and hospital medical records.[Both serum periostin and the Asthma Exacerbation Questionnaire will be performed on Day 1 at the enrollment visit. GP and hospital medical records will be assessed retrospectively starting from the date of their first visit at the Medical Research Institute to the date of their reassessment.]